ダウンロード数: 243

このアイテムのファイル:
ファイル 記述 サイズフォーマット 
39_725.pdf4.96 MBAdobe PDF見る/開く
タイトル: ヒトリンパ芽球インターフェロンとUFTの併用療法が奏効した進行性腎細胞癌の1症例
その他のタイトル: Successful management for advanced renal cell carcinoma under combination therapy with human lymphoblastoid interferon-alpha and UFT (mixture of tegafur and uracil): a case report
著者: 菅野, ひとみ  KAKEN_name
北見, 一夫  KAKEN_name
仙賀, 裕  KAKEN_name
高橋, 俊博  KAKEN_name
長嶋, 洋治  KAKEN_name
著者名の別形: Kanno, Hitomi
Kitami, Kazuo
Senga, Yutaka
Takahashi, Toshihiro
Nagashima, Yoji
キーワード: Renal cell carcinoma
Interferon-a
UFT
発行日: Aug-1993
出版者: 泌尿器科紀要刊行会
誌名: 泌尿器科紀要
巻: 39
号: 8
開始ページ: 725
終了ページ: 729
抄録: We report a case of renal cell carcinoma in a 76-year-old man with pulmonary metastasis and tumor thrombus in inferior vena cava. The patient responded to the combination therapy with a small amount of HLBI (human lymphoblastoid interferon-alpha) and UFT (1:4 mixture of tegafur and uracil). HLBI was administered intramuscularly at a dose of 3 x 10(6) IU two times a week. However, the administration of the same dose was discontinued, because of the severe side effects, such as depression, general fatigue, anorexia and high fever. Finally, the maximum dose was determined to be 2 x 10(6) IU/week. Nine weeks after the first treatment, UFT was simultaneously given orally at a dose of 100 mg/day for potentiating the antitumor effect. At 12 weeks, the patient registered complete response of pulmonary metastasis, and partial response (83% reduction) of renal tumor. About 60 x 10(6) IU HLBI was administered until the response was noted. After 34 weeks of administration of HLBI, nephrectomy was performed. Histological diagnosis was renal cell carcinoma of clear cell subtype, grade 2. Microscopically, many lymphocytes infiltrated into the cancer cells. This suggests the possibility of immunological response caused by HLBI.
URI: http://hdl.handle.net/2433/117908
PubMed ID: 8379474
出現コレクション:Vol.39 No.8

アイテムの詳細レコードを表示する

Export to RefWorks


出力フォーマット 


このリポジトリに保管されているアイテムはすべて著作権により保護されています。